Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 7/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.51 |
| ▸ | CDK1 | P06493 | 5/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13949522 | 0.86 | KDM4E (0.68) | KDM4ELMNAALDH1A1HPGDMAPT | |
| SCHEMBL16433459 | 0.83 | KIF11 (0.49) | KDM4ELMNAALDH1A1HPGDMAPT | |
| SCHEMBL6646914 | 0.82 | KDM4E (0.51) | KDM4EMEN1KMT2AGSK3BCDK5 | |
| SCHEMBL4234216 | 0.81 | KDM4E (0.68) | KDM4ELMNAALDH1A1HPGDMAPT | |
| SCHEMBL11271957 | 0.80 | KDM4E (0.66) | KDM4ELMNAALDH1A1HPGDMAPT | |
| SCHEMBL4156339 | 0.80 | KDM4E (0.61) | KDM4ELMNAALDH1A1HPGDMAPT | |
| SCHEMBL6240551 | 0.80 | PTGES (0.51) | KDM4ELMNAALDH1A1MAPTGAA | |
| SCHEMBL6354898 | 0.80 | PTGES (0.51) | KDM4ELMNAALDH1A1MAPTGAA | |
| SCHEMBL18580499 | 0.79 | MAPT (0.59) | KDM4ELMNAALDH1A1MAPTMEN1 | |
| SCHEMBL4031072 | 0.78 | KDM4E (1.00) | KDM4ELMNAALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458121-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-05-21 | — | — | US | disclosed |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-05-21 | — | — | US | disclosed |
| WO-2019005841-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005841-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-03 | — | — | WO | disclosed |
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| EP-1824476-A2 | TETRAHYDROCARBAZOLE DERIVATIVES FOR TREATING FLAVIRIDAE VIRUSES | SmithKline Beecham Corporation (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1817026-A2 | HCV INHIBITORS | SmithKline Beecham Corporation (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060281804-A1 | Novel cycloalkyl'b! condensed indoles | SMITHKLINE BEECHAM CORPORATION | 2006-12-14 | — | — | US | disclosed |
| WO-2006121467-A2 | TETRAHYDROCARBAZOLE DERIVATIVES FOR TREATING FLAVIRIDAE VIRUSES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121466-A2 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| US-20060161002-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-20 | — | — | US | disclosed |
| EP-1658068-A1 | NOVEL CYCLOALKYL'B! CONDENSED INDOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1654228-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005023245-A1 | NOVEL CYCLOALKYL’B! CONDENSED INDOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004110999-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11458121-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC10A1, SLC47A1 | KDM4E 4461/4885LMNA 4360/4885ALDH1A1 617/4885 |
| US-20060161002-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | HMBS, UGT2B17, TPMT | KDM4E 1909/4885LMNA 2715/4885ALDH1A1 1218/4885 |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | KDM4E 4461/4885LMNA 4360/4885ALDH1A1 617/4885 |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | VEGFA, FLT4, KDR | KDM4E 518/4885LMNA 4109/4885ALDH1A1 2199/4885 |
| US-20060281804-A1 | Novel cycloalkyl'b! condensed indoles | BCCIP, TP53, TOP2B | KDM4E 2101/4885LMNA 2198/4885ALDH1A1 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.